AI labs will need advanced gene editing to address many of the diseases they pursue, making Prime Medicine's strategic importance hard to overstate as they expand into biology. Cystic fibrosis is a sizable indication; demonstrating the technique works there could open larger indications. x.com  x.com  x.com 

Prime Medicine's stock should start to move once more pipeline data comes in, building on amazing technology and early results in a rare immune disease showing quick fixes. More programs are coming, and its cash runway lasts until 2027. x.com 

Prime Medicine will trade on hype and fumes until it shows positive clinical data, likely not before sometime in 2027, because it is still a Phase 1 company. Its technology reads as almost too good to be true, but genomics has many promising players and it is hard to know now who will win, which favors a broad genomics ETF over a single name. x.com 

Bristol Myers Squibb and Merck look expensive given the market's optimism about their patent cliffs. Bristol Myers trades at 13x and Merck at 16x 2028 EV/FCF, versus Regeneron at 9.5x, which is ridiculous. As @PCM_bio notes, Opdivo loses exclusivity in 587 days and Bristol has done little to address that or its other patent expirations. x.com  x.com 

Bristol Myers Squibb offers a strong drug pipeline and a 4.3% dividend, making it a slow but safe long-term holding. It sits in one of the market's largest bullish ascending triangles, with a 350% gain projected to complete Wave 5. x.com 

Prime Medicine and Beam Therapeutics show yellow flags, if not red, in their shared founder and IP dispute, even though prime editing is one of this century's most critical technologies. The same academic scientist helped found both yet stayed at his university rather than run either full time. Now the two companies are in arbitration over IP and contractual rights. Something may be missing here, and hopefully is, but these are not green flags. x.com 

Small- and mid-cap biotech looks like one of healthcare's more asymmetric setups after a four-year bear market, as AI speeds drug discovery and Big Pharma faces a patent cliff. Over $300B of pharma revenue goes off patent in the next few years, M&A is already ramping hard as pharma hunts for assets, and many small and mid-cap names still trade at reasonable valuations, making them potential takeover targets. x.com 

Prime Medicine's management has made a mess of the business case. Deprioritizing the CGD program, along with a CEO change and layoffs, was net negative: a proof point paired with a program cut hurt the platform's credibility, made investors question management's vision and killed the investment narrative. That raised the cost of capital, since new equity at $3 is far more dilutive. The editing tech is brilliant, but with founder Liu staying at the university, the business is unconvincing. x.com  … Show more